Supplementary Figures S1-S5 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors

Supplementary Figures S1-S5. Timelines for acquired resistance and resensitization (S1); Assessment of copy number changes in additional subclones (S2); RS lines behave like original parent cells with return of ALK expression to baseline (S3); Reselection of resensitized cells again selects for up-regulation of NPM-ALK and the resistant-dependent phenotype (S4); Assessing whether an up-front intermittent dosing regimen prolongs tumor control in vivo (S5).